Please use this identifier to cite or link to this item:
Title: Protocol for the economic evaluation of COVID-19 pandemic response policies
Authors: Chua, Brandon Wen Bing 
Vinh Anh Huynh 
Lou, Jing 
Goh, Fang Ting 
Clapham, Hannah 
Teerawattananon, Yot 
Wee, Hwee Lin 
Keywords: COVID-19
health economics
health services administration & management
public health
Issue Date: 1-Sep-2021
Publisher: BMJ Publishing Group
Citation: Chua, Brandon Wen Bing, Vinh Anh Huynh, Lou, Jing, Goh, Fang Ting, Clapham, Hannah, Teerawattananon, Yot, Wee, Hwee Lin (2021-09-01). Protocol for the economic evaluation of COVID-19 pandemic response policies. BMJ Open 11 (9) : e051503. ScholarBank@NUS Repository.
Rights: Attribution 4.0 International
Abstract: Introduction Several treatment options are available for COVID-19 to date. However, the use of a combination of non-pharmaceutical interventions (NPIs) is necessary for jurisdictions to contain its spread. Although the implementation cost of NPIs may be low from the healthcare system perspective, it can be costly when considering the indirect costs from the societal perspective. COVID-19 vaccination campaigns have begun in several countries worldwide. Nonetheless, the quantity of vaccines available remain limited over the next 1 to 2 years. A tool for informing vaccine prioritisation that considers both cost and effectiveness will be highly useful. This study aims to identify the most cost-effective combination of COVID-19 response policies, using Singapore as an example. Methods and analysis An age-stratified Susceptible-Exposed-Infectious-Recovered model will be used to generate the number of infections stratified by disease severity under different intervention scenarios. Polices of interest include test-trace-isolate, travel restriction, compulsory face mask and hygiene practices, social distancing, dexamethasone/remdesivir therapy and vaccination. The latest phase 3 trial results and the WHO Target Product Profiles for COVID-19 vaccines will be used to model vaccine characteristics. A cost (expected resource utilisation and productivity losses) and quality-adjusted life years (QALYs) will be attached to these outputs for a cost-utility analysis. The primary outcome measure will be the incremental cost-effectiveness ratio generated from the incremental cost of policy alternatives expressed as a ratio of the incremental benefits (QALYs gained). Efficacy of policy options will be gathered from literature review and from its observed impacts in Singapore. Cost data will be gathered from healthcare institutions, Ministry of Health and published data. Sensitivity analysis such as threshold analysis and scenario analysis will be conducted. Ethics and dissemination Ethics approval was not required for this study. The study findings will be disseminated through peer-reviewed journals. © Author(s) (or their employer(s)) 2021.
Source Title: BMJ Open
ISSN: 2044-6055
DOI: 10.1136/bmjopen-2021-051503
Rights: Attribution 4.0 International
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1136_bmjopen-2021-051503.pdf950.21 kBAdobe PDF



Google ScholarTM



This item is licensed under a Creative Commons License Creative Commons